Trial Profile
A PHASE 2 DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY, TOLERABILITY AND PHARMACOKINETICS/ PHARMACODYNAMICS OF PF-04360365 IN MILD TO MODERATE ALZHEIMER'S DISEASE PATIENTS
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Apr 2024
Price :
$35
*
At a glance
- Drugs Ponezumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
- 19 Jul 2012 Results presented at the 2012 International Conference on Alzheimer's Disease.
- 17 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.